Propranolol in the treatment of migraine.

Abstract

Beta-blocking drugs that prevent cranial vasodilatation are potentially valuable in the prophylaxis of migraine. Forty-nine patients with either classic or common migraine were treated with propranolol 160 mg/day for an average of six months. The first 30 of the patients to respond well to this treatment then participated in a double-blind cross-over trial with a placebo and propranolol. The mean frequency of headache attacks was significantly reduced by propranolol. None of the patients expressed a preference for placebo. Propranolol seems to be an effective prophylactic for common and classic migraine but the antimigraine properties of the various beta-blocking agents probably differ.

• Authors: T E Wideroe, T Vigander
• Journal: British medical journal (Br Med J) Vol. 2 Issue 5921 Pg. 699-701 (Jun 29 1974) ISSN: 0007-1447 [Print] England
• PMID: 4604977 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Placebos
• Propranolol

Topics

• Clinical Trials as Topic
• Female
• Humans
• Male
• Migraine Disorders (drug therapy, prevention & control)
• Placebos
• Propranolol (adverse effects, pharmacology, therapeutic use)
• Respiration (drug effects)
• Respiratory Tract Diseases (chemically induced)